Bottom line
JSIGX vs SPSM: the short answer
JSIGX (Jacob Small Cap Growth Fund) and SPSM (State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF) are both mutual funds.
But SPSM is far broader, holding 613 positions to 33 for JSIGX, so beyond the top names it adds exposure JSIGX doesn't have.
SPSM is cheaper at 0.03% vs 2.96% — a difference of $293 a year per $10,000 invested.
Over five years, SPSM returned +7.3% a year vs −1.1% for JSIGX (reporting dates differ).
Updated Nov 19, 2026
JSIGX vs SPSM side by side
| JSIGX | SPSM | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Jacob | SPDR (State Street) |
| Category | Small-Cap | Small-Cap |
| Expense ratio | 2.96% | 0.03% |
| Annual cost per $10k | $296 | $3 |
| 10-yr cost on $10k (prospectus) | $3,954 | $39 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +42.0% | +6.0% |
| 5-yr return (annualized) | −1.1% | +7.3% |
| 10-yr return (annualized) | +10.0% | +9.5% |
| Best quarter | — | +31.3% |
| Worst quarter | — | −32.7% |
| Net assets (fund) | $8.3M | $16.9B |
| Number of holdings | 33 | 613 |
| Portfolio turnover | 58% | 3% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
JSIGX and SPSM share none of their top holdings.
JSIGX top 10
- First American Government Obli — 8.21%
- Celcuity Inc — 6.90%
- Circle Internet Group Inc — 5.05%
- Alphatec Holdings Inc — 4.93%
- Beam Therapeutics Inc — 4.85%
- Omeros Corp — 4.80%
- Harrow Inc — 4.64%
- Codexis Inc — 4.52%
- DraftKings Inc — 4.20%
- Powerfleet Inc NJ — 4.18%
SPSM top 10
- State Street Global Advisors — 5.85%
- FormFactor Inc — 0.68%
- Viasat Inc — 0.66%
- Molina Healthcare Inc — 0.65%
- Argan Inc — 0.60%
- BrightSpring Health Services Inc — 0.60%
- Element Solutions Inc — 0.59%
- MaxLinear Inc — 0.58%
- Krystal Biotech Inc — 0.53%
- ESCO Technologies Inc — 0.49%
FAQ
What is the difference between JSIGX and SPSM?
Which is cheaper, JSIGX or SPSM?
Should I own both JSIGX and SPSM?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.